Establishment of immuno-stimulatory antibody therapy against cancer

2016 Fiscal Year Final Research Report

• Project/Area Number: 26290059
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Tumor therapeutics
• Research Institution: Juntendo University
• Principal Investigator: YAGITA Hideo 順天堂大学, 医学部, 准教授 (30182306)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: がん / 免疫 / 抗体療法 / キラーT細胞 / CD27 / CTLA-4 / PD-1 / VISTA

Outline of Final Research Achievements

We have developed novel strategies to enhance the immunogenic cell death of cancer cells indued by anti-DR5 monoclonal antibody and to reduce its unfavorable side effect. We have also developed a novel monoclonal antibody that can directly induce unique cell death in human leukemias. We have further developed novel strategies to augment anti-tumor immunity by using antibodies activating the immunostimulatory pathways (such as CD137, CD27, and Notch2) and those blocking the immunosuppressive pathways (such as CTLA-4, PD-1, TIM-3, VISTA, and TIGIT) in combination with standard chemotherapy, radiotherapy, and antibody therapy targeting cancer cells.

Free Research Field

免疫学